Presbia will participate at the XXXV Congress of the European Society of Cataract and Refractive Surgeons (ESCRS), Europe’s leading organization for cataract and refractive surgeons, to be held in Lisbon, Portugal on October 7th through 11th.
The Presbia Flexivue Microlens is currently approved for sale in 42 countries around the world. The company is planning to make its final submission to the FDA before the end of 2017 in anticipation of approval in 2018. Several surgeons who have implanted the Presbia Flexivue Microlens commercially and as part of the FDA study will be sharing their hands-on experience with the product at ESCRS.
Prof. Tae Young Chung, who is conducting a clinical study with the Presbia Flexivue Microlens at Samsung Medical Center in South Korea, will present at the ESCRS congress.
Prof. Pallikaris, who has experience with the Presbia Flexivue Microlens since 2007, is participating in an Instructional Course titled “Corneal Inlay Technologies for the Treatment of Presbyopia."
On October 5, Dr. Fantozzi, who first performed the Presbia Flexivue Microlens procedure over 7 years ago, will present long-term results at the Presbymania event, an event where experts from around the world gather to discuss the surgical treatment of presbyopia.
Karl Stonecipher, MD, a clinical investigator who is participating in the FDA pivotal study of the Presbia Flexivue Microlens, will also conduct a presentation at the International Society of Presbyopia (ISOP) that is being held at the Saba Lisboa Hotel on October 6 in Lisbon.
Todd Cooper, President and CEO of Presbia, will give a presentation at the Ophthalmology Futures European Forum, focusing on the transformation of presbyopia correction with the Presbia Flexivue Microlens. This will take place on Thursday, October 5 at the Myriad Crystal Center, Lisbon, Portugal.
“Presbia’s presentations being held at ESCRS and at ISOP will increase industry leaders’ awareness of the positive results that have been consistently reported globally by surgeons and patients using our Microlens as the treatment for near-vision loss,” Todd Cooper, President and CEO of Presbia, said in a company news release. “Surgeons will have an opportunity for hands-on experience with our product at the Presbia booth, enabling them to experience our unique presbyopia solution.”
Presbia representatives will be available for one-on-one meetings at booth number P288 during the ESCRS.